

DAVID Y. IGE
GOVERNOR



STATE OF HAWAII
DEPARTMENT OF PUBLIC SAFETY

919 Ala Moana Boulevard, 4th Floor
Honolulu, Hawaii 96814

NOLAN P. ESPINDA
DIRECTOR

Cathy Ross
Deputy Director
Administration

Jodie F. Maesaka-Hirata
Deputy Director
Corrections

Renee R. Sonobe Hong
Deputy Director
Law Enforcement

No. _____

TESTIMONY ON HOUSE BILL 1602, HOUSE DRAFT 1
RELATING TO OPIOIDS

by

Nolan P. Espinda, Director
Department of Public Safety


House Committee on Consumer Protection and Commerce
Representative Roy M. Takumi, Chair
Representative Linda Ichiyama, Vice Chair

Wednesday, February 21, 2017; 2:00 p.m.
State Capitol, Conference Room 329

Chair Takumi, Vice Chair Ichiyama, and Members of the Committee:

The Department of Public Safety (PSD) **supports the intent** of House Bill (HB) 1602, House Draft (HD) 1, which would permit the inclusion of a label warning of the risks of addiction and death on the packaging of any opioid drug dispensed by a health care professional or pharmacist. PSD also recommends that the proposed warning in HB1602, HD 1 may be included on literature, provided to the patient, when opioid drugs are dispensed by practitioners and pharmacists.

Thank you for the opportunity to present this testimony.



STATE OF HAWAII
DEPARTMENT OF HEALTH
P. O. Box 3378
Honolulu, HI 96801-3378
doh.testimony@doh.hawaii.gov

**Testimony COMMENTING on HB 1602 HD 1
RELATING TO OPIOIDS**

REPRESENTATIVE ROY M. TAKUMI, CHAIR
HOUSE COMMITTEE ON CONSUMER PROTECTION & COMMERCE

Hearing Date: February 21, 2018

Room Number: 329

1 **Fiscal Implications:** Undetermined

2 **Department Testimony:** This measure intends to educate patients about the dangers of opioid
3 use. The Department of Health (DOH) applauds the intent of this bill and recognizes the
4 commitment of the sponsors of this measure to step up state efforts to combat the opioid
5 epidemic through multi-faceted strategies such as warning labels and comprehensive health
6 insurance coverage for opioid treatment.

7 The DOH defers to the Department of Public Safety regarding the implementation of the
8 amendment to HRS Chapter 329E.

9 The DOH Alcohol and Drug Abuse Division (ADAD) believes that the prevalence of
10 substance use disorders encompass a wide variety of substances besides opioids and many who
11 suffer from the chronic illness of substance abuse, misuse multiple drugs. The ADAD is
12 committed to addressing both opioid misuse as well as the broader addiction problem in Hawaii
13 and has been working closely with other government and community entities to coordinate a
14 comprehensive response plan to address opioids and substance abuse in general. From a wider
15 chronic illness perspective, substance misuse and addiction represents significant public health
16 and economic burdens for Hawaii. This is presented in more detail in the Hawaii Opioid Action
17 Plan, which is found at: [https://health.hawaii.gov/substance-abuse/files/2013/05/The-Hawaii-](https://health.hawaii.gov/substance-abuse/files/2013/05/The-Hawaii-Opioid-Initiative.pdf)
18 [Opioid-Initiative.pdf](https://health.hawaii.gov/substance-abuse/files/2013/05/The-Hawaii-Opioid-Initiative.pdf)

19 According to the Hawaii Opioid Action Plan (Dec. 2017):

- 1 • There is an average of nearly 400 nonfatal overdose incidents each year, nearly
2 half of which require hospitalization; and
- 3 • The issue of opioid misuse and addiction cannot be fully appreciated unless seen
4 from a broader context of a chronic illness perspective, which shows that
5 substance misuse and addiction represents significant public health and economic
6 burdens for Hawaii:
- 7 ○ Workplace drug tests positive for methamphetamine were 410% higher
8 than the national average in 2011;
- 9 ○ Impaired driving deaths in Hawaii (2010-2014) were 39.4% compared to
10 the national average of 30.0%; and
- 11 ○ Data from ADAD-funded providers suggests that methamphetamine was
12 reported as the primary drug of choice upon admission for 53.4% of adults
13 receiving substance misuse treatment in FY2017.

14 Treatment admission data from 2010-2016 in Hawaii further underscores the need for a
15 focus on the broader addiction issue in the state and for a coordinated and comprehensive
16 approach to addiction in Hawaii.

17 Thank you for the opportunity to provide testimony.



HAWAII CHAPTER - AMERICAN PHYSICAL THERAPY ASSOCIATION

(800) 554-5569 x13 • www.hapta.org • info@hapta.org

**HB 1602hd1, Relating to Opioids
CPC Committee Hearing
Thursday, Feb. 21, 2018 –
2:00 pm Room 329
Position: Support**

Chair Takumi, Vice Chair Ichiyama and Members of the Consumer Protection and Commerce Committee:

I am Gregg Pacilio, PT and Board President of the Hawaii Chapter of the American Physical Therapy Association (HAPTA), a non-profit professional organization serving more than 340 member Physical Therapists and Physical Therapist Assistants. Our members are employed in hospitals and health care facilities, the Department of Education school system, and private practice. We are movement specialists and are part of the spectrum of care for Hawaii, and provide rehabilitative services for infants and children, youth, adults and the elderly. Rehabilitative services are a vital part of restoring optimum functioning from neuromusculoskeletal injuries and impairments.

HAPTA **supports** the requirement of warning labels on Opioid prescriptions warning of potential addiction and harm. As physical therapists, our professional association, The American Physical Therapy Association (APTA), has started a movement within our profession to fight the growing epidemic of opioid addiction. The APTA and the Hawai'i chapter (HAPTA) have adopted the #choosePT tag to help bring attention to this growing non-injury or disease related cause of death. So we continue to support any means that align with our goals to promote the choice of alternative methods of treatment and decrease the abuse of opioids in health care.

Your support of HB 1602hd1 is appreciated. Thank you for the opportunity to testify. Please feel free to contact Justin Ledbetter, HAPTA's Wellness Issue Lead at (334) 740-0323 for further information.

HB-1602-HD-1

Submitted on: 2/20/2018 12:02:40 AM

Testimony for CPC on 2/21/2018 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Melodie Aduja	OCC Legislative Priorities Committee, Democratic Party of Hawai'i	Support	No

Comments:

**PRESENTATION OF THE
OAHU COUNTY COMMITTEE ON LEGISLATIVE PRIORITIES
DEMOCRATIC PARTY OF HAWAII'**

TO THE COMMITTEE ON CONSUMER PROTECTION & COMMERCE

THE HOUSE OF REPRESENTATIVES

TWENTY-NINTH LEGISLATURE

REGULAR SESSION OF 2018

Wednesday, February 21, 2018

2:00 p.m.

Hawaii State Capitol, Conference Room 329

RE: Testimony in Support of HB 1602 HD1 RELATING TO OPIOIDS

To the Honorable Roy M. Takumi, Chair; the Honorable Linda Ichiyama, Vice-Chair, and Members of the Committee on Consumer Protection & Commerce:

Good morning, my name is Melodie Aduja. I serve as Chair of the Oahu County Committee ("OCC") Legislative Priorities Committee of the Democratic Party of Hawaii. Thank you for the opportunity to provide written testimony on House Bill No.1602 HD1 relating to opioids and warning labels.

The OCC Legislative Priorities Committee is in favor of House Bill No. 1602 HD1 and support its passage.

House Bill No. 1602 HD1 is in alignment with the Platform of the Democratic Party of Hawai'i ("DPH"), 2016, as it permits the inclusion of a label warning of the risks of addiction and death on the packaging of any opioid drug dispensed by a health care professional or pharmacist.

The DPH Platform states that "[w]e support community health initiatives that provide opportunities for the overall health of communities through strategic projects and programs focusing on increased interaction and physical activities among all age groups, as well as on better nutrition.

We also support the establishment of adequate mental health and statewide drug rehabilitation programs set up in conjunction with policing policies aimed at enabling all that seek assistance to obtain whatever support assistance is needed to allow them to remain free of drug dependence.(Platform of the DPH, P. 7, Lines 378-384 (2016)).

Given that House Bill No. 1602 HD1 permits the inclusion of a label warning of the risks of addiction and death on the packaging of any opioid drug dispensed by a health care professional or pharmacist, it is the position of the OCC Legislative Priorities Committee to support this measure.

Thank you very much for your kind consideration.

Sincerely yours,

/s/ Melodie Aduja

Melodie Aduja, Chair, OCC Legislative Priorities Committee

Email: legislativepriorities@gmail.com, Tel.: (808) 258-8889



HB1602 HD1 Labeling Opioid Prescription Containers

COMMITTEE ON CONSUMER PROTECTION & COMMERCE:

- Representative Roy Takumi, Chair; Representative Linda Ichiyama, Vice Chair
- Wednesday, February 21st, 2018: 2:00 pm
- Conference Room 329

HAWAII SUBSTANCE ABUSE COALITION (HSAC) Supports the Intent for HB1602 HD1 and Recommends More Discussion:

GOOD MORNING CHAIR, VICE CHAIR AND DISTINGUISHED COMMITTEE MEMBERS. My name is Alan Johnson. I am the current chair of the Hawaii Substance Abuse Coalition (HSAC), a statewide hui of almost 40 alcohol and drug treatment and prevention agencies.

While HSAC agrees with the intent of the bill, there are considerations to discuss in a more comprehensive manner before labeling a drug.

HSAC wholeheartedly agrees with the language in the narrative in Section 1 that:

1. More comprehensive health insurance coverage is needed for the treatment of opioid dependence;
2. Data collection on opioid overdoses and deaths must be more comprehensive.

Recommendations

More discussion is needed before determining the following:

1. What are the regulatory environments and enforcement provisions that would impact the implementation of such label warnings to accompany opioid prescriptions;
2. What would be the lowest possible dosage levels for prescriptions since this involves doctors determining medical necessity;
3. The font size is too big for small bottles.

We appreciate the opportunity to provide testimony and are available for questions.



SanHi

GOVERNMENT STRATEGIES

A LIMITED LIABILITY LAW PARTNERSHIP

DATE: February 20, 2018

TO: Representative Roy Takumi
Chair, Committee on Consumer Protection and Commerce
Submitted Via Capitol Website

RE: **H.B. 1602, H.D.1 Relating to Opioids**
Hearing Date: Wednesday, February 21, 2018 at 2:00 p.m.
Conference Room: 329

Dear Chair Takumi and Members of the Committee on Consumer Protection and Commerce:

We submit this testimony on behalf of Walgreen Co. (“Walgreens”). Walgreens operates stores at more than 8,200 locations in all 50 states, the District of Columbia, and Puerto Rico. In Hawaii, Walgreens now has 19 stores on the islands of Oahu, Maui, and Hawaii.

Walgreens **supports the intent of H.B.1602 with amendments**, which permits the inclusion of a label warning of the risks of addiction and death on the packaging of any opioid drug dispensed by a health care professional or pharmacist.

Walgreens is committed to comprehensive efforts to combat drug abuse and has supported several measures to help with the opioid crisis. While not opposed to a warning label, we would also note that any policy regarding opioid warning labels needs to be balanced against having the opposite impact, where adding visuals could make opioids more attractive among other medications.

Walgreens appreciates the amendments made to the H.D.1 version of this bill, which made an opioid label permissive and removed the mandatory font requirement. Because different pharmacies have different limitations, we believe it would be best to make a warning as simple as possible to implement.

There are also other instructions on a bottle that also need to be included and provide important information about opioids (like dosage, other side effects etc). Based on these concerns we would suggest that the bill remove the current wording of the warning and/or significantly shorten the warning language and allow flexibility for using similar wording to comply.

We are happy to work with the committee on this measure and offer language if needed. Thank you for the opportunity to submit testimony regarding this bill.

LATE

HB-1602-HD-1

Submitted on: 2/21/2018 7:19:24 AM
Testimony for CPC on 2/21/2018 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
SueAnn Yasuoka	Individual	Oppose	No

Comments:

Feb. 21, 2018

Committe on Consumer Protection and Commerce

Re: HB 1950

As a RETAIL pharmacist in the Community, I support the intent of this Bill, but OPPOSE the legislation to REQUIRE the pharmacist to label the prescription. We will look into this label and provide it but don't want to be mandated.

Sincerely,

SueAnn Yasuoka

LATE

HB-1602-HD-1

Submitted on: 2/20/2018 10:16:09 PM
Testimony for CPC on 2/21/2018 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Rachel L. Kailianu	Ho`omana Pono, LLC	Support	Yes

Comments: